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ABSTRACT
Vitiligo is an acquired cutaneous
depigmentation disorder which has a
deleterious effect on the psychosexual
function of many individuals; the genitalia are
the common site for depigmentation. Here, the
authors report two cases of focal vitiligo
affecting the scrotum of the genital organs
which were successfully treated by autologous
cultured melanocyte transplantation.
Autologous cultured melanocyte
transplantation on the scrotum is shown to be
a relative effective method of treatment for
vitiligo.




Vitiligo is an acquired cutaneous depigmentation
disorder, which has a deleterious effect on the
psychosexual function of many individuals; the
genitalia are the common site for depigmentation
[1].Thereare fewreports about treatmentofgenital
vitiligo [2–5]. Only one report discovered by the
authors refers to depigmentation of the scrotum
[5]. The importance of follicles as a reservoir of
melanocytes is emphasized by the well-known fact
that glabrous skin (i.e., non-hair-bearing skin),
such as genitalia, rarely responds to therapy unless
it has some residual pigment [6]. Therefore, the
treatment of genital vitiligo is difficult. Here, the
authors report two cases of focal vitiligo affecting
the scrotum of the genital organs which were
successfully treated by autologous cultured
melanocyte transplantation.
METHODS
Donor skin was obtained from the patients’
normally pigmented area of the abdomen or
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thighs. Specimens were washed with calcium-
free Hanks’ solution, incubated in 0.25% trypsin
solution for 10 min, followed by incubation with
0.02% ethylenediaminetetraacetic acid (EDTA)
solution for 10 min at 37 C. Cells were separated
from the epidermal sheet under a
stereomicroscope. The cell suspension was
centrifuged, re-suspended with Hu16 medium
(F12 medium with 20 ng/ml basic fibroblast
growth factor, 20 lg/ml 3-isobutyl-1-
methylxanthine, 10 ng/ml cholera toxin, 50 lg/
ml gentamicin, and 10% fetal bovine serum) and
seeded into a culture flask. Cells were incubated
in a humidified 5% CO2 atmosphere at 37 C.
Geneticin (Sigma-Aldrich, Saint Louis, MO, USA)
was added to the medium (100 lg/ml) 3 days
later to eliminate contaminating cells. After
primary cultures became confluent, the
melanocytes were detached by 0.125% trypsin/
0.01% EDTA solution, centrifuged, re-
suspended, diluted at a ratio of 1:2–1:3, and
seeded into culture flasks for subculture. After the
cell number met the requirement for
transplantation (approximately
80,000 melanocytes/cm2), the melanocytes were
detached as described above, centrifuged, re-
suspended in F12 medium, and transferred to
the operating room for transplantation in a timely
manner.
A topical anesthetic, lidocaine cream, was
applied 2–4 h before transplantation. The
recipient areas were cleaned with 70% alcohol
and treated with UltraPulse CO2 laser
(Lumenis, Santa Clara, CA, USA; pulse rate
30–50 Hz at an energy level of 225 mJ per
pulse) to remove the epidermis. The
melanocyte suspension was applied to the
laser-denuded area with a pipette at a density
of 80,000 melanocytes/cm2. The recipient site
was immediately covered with silicone gauze,
followed by a gauze-soaked in F12 culture
medium, and, finally, secured with Tegaderm
(3 M Health Care Ltd, Laughborough, UK) and
surgical tape. After the procedure, patients were
instructed to recline flat for at least 1 h to allow
successful attachment of the melanocytes to the
recipient site. The patient was cautioned against
any vigorous activities, which could displace
the dressing. All dressings were removed
7–10 days later.
The Ethical Committee of the National Center
for Vitiligo and Psoriasis approved the treatment.
The study was approved by the institutional
review Board of Third People’s Hospital of
Hangzhou, and written informed consent was
obtained from each patient for inclusion in this
study and for publication of the photographs. All
procedures followed were in accordance with the
ethical standards of the Helsinki Declaration of
1975, as revised in 2000 and 2008.
CASE REPORTS
Case 1
A 21-year-old male reported focal vitiligo of
5 years duration affecting the scrotum of the
genital organ. The lesion was non-progressive
for about 4 years. Physical examination revealed
that the depigmentation patch affecting the
scrotum had a total area of 20 cm2. The patient
received the cultured autologous melanocytes
transplantation in November 2011. The donor/
recipient size ratio (DOT) of the melanocytes
was 3.46, and the concentration of melanocytes
applied to the recipient area was 0.197 ng/cell.
Eighteen months post-transplantation, the
vitiliginous area of the scrotum was almost
completely repigmented (Fig. 1). The
depigmented lesion had not received
phototherapy before or after transplantation,
and the patient was very satisfied with the
cosmetic results.
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Case 2
A 16-year-old male was first received in
September 2012 complaining of a
depigmented lesion on the scrotum with a
duration of 3 years. The lesion had not shown
any progress in the last 2 years. The area of the
lesions was 15 cm2. The patient had no family
history of vitiligo. He failed to respond to
medical treatment administered to him
(topical pimecrolimus used for 6 months,
twice daily). The patient underwent
transplantation in September 2012. The DOT
of the melanocytes was 3.24, and the
concentration of melanocytes applied to the
recipient area was 0.186 ng/cell. In the latest
follow-up in September 2013, the authors found
the lesion 95% repigmentation was achieved,
and the patient was very satisfied with the
cosmetic results (Fig. 2).
DISCUSSION
The genital is a commonly affected site for
vitiligo in men, and it is sometimes the only site
affected [7]. The treatment of genital vitiligo is
quite complex. There are very few reports in the
literature for the treatment of genital vitiligo.
Souza Leite et al. [4] reported one case of genital
vitiligo successfully treated by pimecrolimus.
However, this patient had a short duration of
the disease considering the existence of residual
melanocytes. Therefore, the use of medication
was considered to be a better option. For vitiligo
with longer duration or vitiligo without residual
pigment in genitals, surgical intervention is
recommended. Mulekar et al. [3] reported three
cases of focal vitiligo affecting the glans and
shaft of the penis successfully treated by
antilogous non-cultured melanocyte–
keratinocyte cell transplantation. Differing
from their cases, the current transplantation
site is located on the scrotum, and the scheme
used was autologous cultured melanocyte
transplantation. Mulekar et al. [3] needed to
perform two rounds of surgery to achieve
satisfying repigmentation, whereas the current
authors achieved 90% repigmentation in case 1.
Redondo et al. [5] used a graft of autologous
melanocytes cultured on a denuded amniotic
membrane to treat a patient with a scrotal
lesion and achieved good regimentation.
However, the current study did not use a
denuded amniotic membrane, and achieved
the same effect.
Fig. 1 Vitiligo lesion (20 cm2) in a 21-year-old male
before (a) and 18 months after (b) the transplantation of
autologous cultured melanocytes. A 90% repigmentation
was achieved
Fig. 2 Vitiligo lesion (15 cm2) in a 16-year-old male
before (a) and 12 months after (b) the transplantation of
autologous cultured melanocytes. A 95% repigmentation
was achieved
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Patients with genital vitiligo often hide their
lesions, and postpone their complaints until
they miss the best time for treatment with
medication. Therefore, the development of
surgical interventions is particularly important
for the patients with long duration vitiligo. The
current study indicates that autologous cultured
melanocyte cell transplantation not only
provides an opportunity for patients with large
areas of stable vitiligo, but can also be used as a
very effective treatment for genital vitiligo,
including the scrotum.
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